- Conditions
- Coronary Arteriosclerosis
- Interventions
- Atorvastatin, Pravastatin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2000
- U.S. locations
- 36
- States / cities
- Little Rock, Arkansas • Los Angeles, California • San Diego, California + 30 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–360
of 13,063
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Solid Tumor, Colorectal Cancer, Neuroendocrine Tumors, Small Cell Lung Cancer, Gastric Cancer, Soft Tissue Sarcoma, Anaplastic Thyroid Cancer
- Interventions
- Surufatinib and Tislelizumab _ Part 1, Surufatinib and Tislelizumab _ Part 2
- Drug
- Lead sponsor
- Hutchmed
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 18
- States / cities
- Tucson, Arizona • Duarte, California • Denver, Colorado + 13 more
- Conditions
- Recurrent Head and Neck Squamous Cell Carcinoma
- Interventions
- IMRT, Nivolumab
- Radiation · Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Cleveland, Ohio • Milwaukee, Wisconsin
- Conditions
- PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)
- Interventions
- Miransertib
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 2 Years to 120 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Cincinnati, Ohio + 2 more
- Conditions
- HIV Infections
- Interventions
- Elvucitabine, Lamivudine
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Sacramento, California • Miami, Florida + 5 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- SPN-810, Placebo
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 38
- States / cities
- Culver City, California • Orange, California • Colorado Springs, Colorado + 33 more
- Conditions
- Tourette's Disorder
- Interventions
- Aripiprazole
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 7 Years to 18 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 36
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Los Angeles, California + 31 more
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Lp(a) Screening
- Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 39,480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 113
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 97 more
- Conditions
- Methylmalonic Acidemia, Propionic Acidemia
- Interventions
- HST5040, Placebo
- Drug
- Lead sponsor
- HemoShear Therapeutics
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 14
- States / cities
- San Diego, California • New Haven, Connecticut • Washington D.C., District of Columbia + 11 more
- Conditions
- Osteoarthritis
- Interventions
- Unilateral Bone Marrow Procurement, Bilateral Bone Marrow Procurement
- Procedure
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Major Depressive Disorder
- Interventions
- Antidepressant + Aripiprazole
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,002 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 58
- States / cities
- Mesa, Arizona • Peoria, Arizona • Beverly Hills, California + 55 more
- Conditions
- Haemophilia A, Haemophilia A With Inhibitors
- Interventions
- NNC0365-3769 (Mim8)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 281 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 28 more
- Conditions
- Ischemic Stroke, Chronic Stroke, Hemiparesis, Arm Paralysis
- Interventions
- CTX0E03 Drug Product and delivery device, Placebo
- Combination Product · Drug
- Lead sponsor
- ReNeuron Limited
- Industry
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 23
- States / cities
- Little Rock, Arkansas • Irvine, California • Los Angeles, California + 19 more
- Conditions
- Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma, Gingival Squamous Cell Carcinoma, Hard Palate Squamous Cell Carcinoma, Lip Squamous Cell Carcinoma, Lower Alveolar Ridge Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Retromolar Trigone Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Tongue Squamous Cell Carcinoma, Upper Alveolar Ridge Squamous Cell Carcinoma
- Interventions
- Chest Radiography, Computed Tomography, Fludeoxyglucose F-18, Imaging Agent, Neck Dissection, Planar Imaging, Positron Emission Tomography, Questionnaire Administration, Sentinel Lymph Node Biopsy, Single Photon Emission Computed Tomography
- Procedure · Other · Drug
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 686 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2036
- U.S. locations
- 106
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 80 more
- Conditions
- Colonoscopy
- Interventions
- BLI4700, Polyethylene glycol bowel preparation
- Drug
- Lead sponsor
- Braintree Laboratories
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 620 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 23
- States / cities
- Mobile, Alabama • Tucson, Arizona • Anaheim, California + 20 more
- Conditions
- Participants Less Than 12 Months of Age With RSV Illness
- Interventions
- Motavizumab, Placebo
- Biological · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 0 Months to 12 Months
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 31
- States / cities
- Tucson, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 24 more
- Conditions
- EBV Infection, Stage II Nasopharyngeal Carcinoma AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage IVA Nasopharyngeal Carcinoma AJCC v7, Stage IVB Nasopharyngeal Carcinoma AJCC v7
- Interventions
- Bone Scan, Cisplatin, Clinical Observation, Computed Tomography, Fluorouracil, Gemcitabine Hydrochloride, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Paclitaxel, Positron Emission Tomography, Quality-of-Life Assessment
- Procedure · Drug · Other + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 924 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2034
- U.S. locations
- 197
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Auburn, California + 150 more
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- dolutegravir
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 42
- States / cities
- Beverly Hills, California • Fountain Valley, California • Los Angeles, California + 32 more
- Conditions
- Lysosomal Acid Lipase Deficiency
- Interventions
- There is no intervention in the study
- Other
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years to 16 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Houston, Texas
- Conditions
- Atrial Fibrillation
- Interventions
- Pulse Field Ablation
- Device
- Lead sponsor
- Biosense Webster, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 362 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 23 more
- Conditions
- Asthma
- Interventions
- GSK3511294, Placebo
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 397 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 41
- States / cities
- Alabaster, Alabama • Mobile, Alabama • Phoenix, Arizona + 34 more
- Conditions
- Chin Augmentation
- Interventions
- Restylane Lyft with Lidocaine
- Device
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 8
- States / cities
- Westport, Connecticut • Boynton Beach, Florida • Coral Gables, Florida + 4 more
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Malignant Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Histiocytic and Dendritic Cell Neoplasm, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Malignant Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Wilms Tumor
- Interventions
- Pharmacokinetic Study, Ulixertinib
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 105
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 82 more
- Conditions
- Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
- Interventions
- Magnetic Resonance Imaging, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia